A Randomized, Double‐Blind, Placebo‐Controlled, Twelve‐Week, Dose‐Ranging Study of Decernotinib, an Oral Selective JAK‐3 Inhibitor, as Monotherapy in Patients With Active Rheumatoid Arthritis

Publisher: John Wiley & Sons Inc

E-ISSN: 2326-5205|67|2|334-343

ISSN: 2326-5191

Source: ARTHRITIS & RHEUMATOLOGY, Vol.67, Iss.2, 2015-02, pp. : 334-343

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content